Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference
Kiora Pharmaceuticals (NASDAQ: KPRX) has announced its participation in the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, 2025, at 2:15 pm EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kiora Pharmaceuticals (NASDAQ: KPRX) has announced its participation in the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, 2025, at 2:15 pm EDT. President & CEO Brian M. Strem, Ph.D., will deliver a presentation updating investors on the company's pipeline developments.
The presentation will focus on two key clinical trials: the planned Phase 2 trials of KIO-104 for retinal inflammation treatment and KIO-301 for retinitis pigmentosa treatment. Investors can access the live presentation through Kiora's investor relations website (ir.kiorapharma.com), with replay available for 90 days on the events page.
Details
News Market Reaction – KPRX
The recorded move for KPRX in the trading session of this news was -7.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Ecinitas, California--(Newsfile Corp. - April 4, 2025) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, 2025, at 2:15 pm EDT.
President & CEO, Brian M. Strem, Ph.D., will provide an update on the progress of the Company's pipeline and its planned Phase 2 clinical trials of KIO-104 for the treatment of retinal inflammation and of KIO-301 for the treatment of retinitis pigmentosa.
The presentation may be accessed live from the homepage of the investor relations section (ir.kiorapharma.com) of Kiora's website and will be available for replay for 90 days on the investor relations "events" page (ir.kiorapharma.com/news-events/events).
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn, as well as to visit our website and/or subscribe to email alerts.
Contacts:
Investors
investors@kiorapharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247286
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.